Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnicoCell Biomed CoTPE:6794 +1.41%80 Current Ratio is 36.82 as of Jun. 2026, which is 34% above its 10-year median of 27.55. GuruFocus rates TPE:6794 with a GF Score™ of 80/100 and a GF Value™ of NT$64.94 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, UnicoCell Biomed Co ranks better than 97.52% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. UnicoCell Biomed Co's current ratio for the quarter that ended in Jun. 2026 was 36.82.
UnicoCell Biomed Co has a current ratio of 36.82. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for UnicoCell Biomed Co's Current Ratio or its related term are showing as below:
TPE:6794'
s Current Ratio Range Over the Past 10 Years
Min: 7.64 Med: 27.55 Max: 40.56
Current: 36.82
During the past 9 years, UnicoCell Biomed Co's highest Current Ratio was 40.56. The lowest was 7.64. And the median was 27.55.
TPE:6794's Current Ratio is ranked better than 97.52% of 1411
companies
in the Biotechnology industry
Industry Median: 3.89
vs TPE:6794: 36.82
UnicoCell Biomed Co (TPE:6794) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
UnicoCell Biomed Co Current Ratio Related Terms
UnicoCell Biomed Co Current Ratio Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a Current Ratio of 36.82 as of Jun. 2026. This is 34% above median its historical median of 27.55. Over the past decade, UnicoCell Biomed Co's Current Ratio has ranged from 7.64 to 40.56. According to the industry distribution chart, UnicoCell Biomed Co ranks #35 out of 1411 companies in the Biotechnology industry, placing it in the top 2.5%.
Is UnicoCell Biomed Co's Current Ratio too high?
UnicoCell Biomed Co's current Current Ratio of 36.82 is 34% above median its 10-year median of 27.55. Over the past 10 years, this metric has ranged from a low of 7.64 to a high of 40.56. The Biotechnology industry median Current Ratio is 3.89. UnicoCell Biomed Co's value of 36.82 is 846.5% above this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #35 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #35 out of 1411 companies for Current Ratio. This places UnicoCell Biomed Co in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. UnicoCell Biomed Co's value of 36.82 is 846.5% above this benchmark. Historically, UnicoCell Biomed Co's own Current Ratio has ranged from 7.64 to 40.56 over the past decade. While the company's 10-year median is 27.55 vs. the industry median of 3.89, UnicoCell Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Current Ratio of 36.82 is 846.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Current Ratio is 36.82, which is 34% above median its own 10-year median of 27.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$64.94, compared to a current price of NT$71.80 — trading 10.6% above its estimated fair value. The current Current Ratio is 36.82, which is 34% above median its 10-year median of 27.55 and 846.5% above the Biotechnology industry median of 3.89. UnicoCell Biomed Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Current Ratio is 36.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be overvalued.
The current stock price of NT$71.80 is trading 10.6% above its estimated GF Value™ of NT$64.94.
GuruFocus considers UnicoCell Biomed Co to be Modestly Overvalued.
Key valuation signals for TPE:6794:
Current Ratio: 36.82 (34% above median its 10-year median of 27.55)
GF Value™: NT$64.94 vs. price of NT$71.80 (10.6% above fair value)
Industry Position: 846.5% above the Biotechnology median (#35 of 1411)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
80GF Score
Get the complete analysis for TPE:6794
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
